[8-K] MERIT MEDICAL SYSTEMS INC Reports Material Event
Merit Medical Systems (MMSI) announced a definitive asset purchase agreement to acquire the C2 CryoBalloon device and related technology from Pentax of America, Inc., a subsidiary of PENTAX Medical. The total purchase consideration is $22 million, including $19 million cash at closing and up to $3 million in contingent payments tied to milestones.
The closing is expected in Q4 2025, subject to satisfaction or waiver of customary closing conditions. Merit referenced non-GAAP measures in its press release and stated that a quantitative reconciliation to GAAP is not available without unreasonable effort.
Merit Medical Systems (MMSI) ha annunciato un accordo definitivo di acquisto di asset per acquisire il dispositivo C2 CryoBalloon e la tecnologia correlata da Pentax of America, Inc., una filiale di PENTAX Medical. Il corrispettivo totale dell'acquisto è $22 milioni, comprensivo di $19 milioni in contanti al momento della chiusura e fino a $3 milioni di pagamenti contingentati legati a traguardi.
La chiusura è prevista nel quarto trimestre del 2025, soggetta al soddisfacimento o al rilascio delle condizioni di chiusura usuali. Merit ha fatto riferimento a misure non-GAAP nel proprio comunicato stampa e ha dichiarato che una riconciliazione quantitativa a GAAP non è disponibile senza sforzi irragionevoli.
Merit Medical Systems (MMSI) anunció un acuerdo definitivo de compra de activos para adquirir el dispositivo C2 CryoBalloon y la tecnología relacionada de Pentax of America, Inc., una filial de PENTAX Medical. El precio total de compra es $22 millones, que incluye $19 millones en efectivo al cierre y hasta $3 millones en pagos contingentes vinculados a hitos.
El cierre está previsto para el cuarto trimestre de 2025, sujeto al cumplimiento o renuncia de las condiciones habituales de cierre. Merit hizo referencia a medidas no GAAP en su comunicado de prensa y afirmó que una conciliación cuantitativa a GAAP no está disponible sin un esfuerzo irrazonable.
Merit Medical Systems (MMSI)는 Pentax of America, Inc., PENTAX Medical의 자회사로부터 C2 CryoBalloon 기기 및 관련 기술을 인수하기 위한 확정 자산 매매 계약을 발표했습니다. 총 매매대금은 $22 million이며, 그 중 종가 시점에 현금으로 $19 million이고 최대 $3 million의 조건부 지급이 이정표와 연계되어 있습니다.
종료는 2025년 4분기에 예정되어 있으며, 일반 종결 조건의 충족 또는 면제 여부에 따라 달라집니다. Merit는 보도자료에서 비-GAAP 지표를 언급했고 GAAP에 대한 정량적 조정은 과도한 노력 없이는 이용할 수 없다고 밝혔습니다.
Merit Medical Systems (MMSI) a annoncé un accord d'achat d'actifs définitif pour acquérir l'appareil C2 CryoBalloon et la technologie associée auprès de Pentax of America, Inc., une filiale de PENTAX Medical. Le prix d'achat total est de $22 millions, comprenant $19 millions en espèces à la clôture et jusqu'à 3 millions de dollars de paiements conditionnels liés à des jalons.
La clôture est prévue au cours du 4e trimestre 2025, sous réserve de l'accomplissement ou du renoncement des conditions de clôture usuelles. Merit a mentionné des mesures non-GAAP dans son communiqué de presse et a déclaré qu'un rapprochement quantitatif vers les GAAP n'était pas disponible sans effort déraisonnable.
Merit Medical Systems (MMSI) hat eine endgültige Asset-Kaufvereinbarung bekannt gegeben, um das C2 CryoBalloon-Gerät und die zugehörige Technologie von Pentax of America, Inc., einer Tochtergesellschaft von PENTAX Medical, zu erwerben. Der gesamte Kaufpreis beträgt $22 Millionen, einschließlich $19 Millionen Bargeld zum Closing und bis zu $3 Millionen an bedingten Zahlungen, die an Meilensteine gebunden sind.
Der Abschluss wird voraussichtlich im vierten Quartal 2025 erfolgen, vorbehaltlich der Erfüllung oder dem Verzicht auf die üblichen Abschlussbedingungen. Merit verwies in seiner Pressemitteilung auf non-GAAP-Maßnahmen und gab an, dass eine quantitative Offenlegung gegenüber GAAP ohne unverhältnismäßigen Aufwand nicht verfügbar ist.
أعلنت Merit Medical Systems (MMSI) عن اتفاقية شراء أصول نهائية لشراء جهاز C2 CryoBalloon والتقنيات المرتبطة من Pentax of America, Inc., وهي شركة فرعية لـ PENTAX Medical. إجمالي قيمة الشراء هو $22 مليون، بما في ذلك $19 مليون نقداً عند الإغلاق و حتى $3 ملايين دولار كمدفوعات مشروطة مرتبطة بمعالم محددة.
من المتوقع الإغلاق في الربع الرابع من 2025، رهناً باستيفاء أو التنازل عن شروط الإغلاق المعتادة. وأشارت Merit إلى مقاييس غير GAAP في بيانها الصحفي وذكرت أن التسوية الكمية إلى GAAP غير متاحة دون جهد غير معقول.
Merit Medical Systems (MMSI)宣布达成一项资产购买协议，以从 Pentax of America, Inc.（PENTAX Medical 的子公司）收购 C2 CryoBalloon 设备及相关技术。总购买对价为 $22 million，其中包括 在交割时现金支付 $19 million，以及 最高 $3 million 的与里程碑相关的或有付款。
预计交割将在 2025 年第四季度，但需满足或放弃常规成交条件。Merit 在新闻稿中提及非 GAAP 措施，并表示在不进行不合理努力的情况下无法提供符合 GAAP 的量化对账。
- None.
- None.
Insights
Small add-on acquisition with defined cash and milestone structure.
Merit Medical signed a definitive agreement to acquire the C2 CryoBalloon technology for a total consideration of
Closing is expected in
Key items to track are completion of closing conditions in
Merit Medical Systems (MMSI) ha annunciato un accordo definitivo di acquisto di asset per acquisire il dispositivo C2 CryoBalloon e la tecnologia correlata da Pentax of America, Inc., una filiale di PENTAX Medical. Il corrispettivo totale dell'acquisto è $22 milioni, comprensivo di $19 milioni in contanti al momento della chiusura e fino a $3 milioni di pagamenti contingentati legati a traguardi.
La chiusura è prevista nel quarto trimestre del 2025, soggetta al soddisfacimento o al rilascio delle condizioni di chiusura usuali. Merit ha fatto riferimento a misure non-GAAP nel proprio comunicato stampa e ha dichiarato che una riconciliazione quantitativa a GAAP non è disponibile senza sforzi irragionevoli.
Merit Medical Systems (MMSI) anunció un acuerdo definitivo de compra de activos para adquirir el dispositivo C2 CryoBalloon y la tecnología relacionada de Pentax of America, Inc., una filial de PENTAX Medical. El precio total de compra es $22 millones, que incluye $19 millones en efectivo al cierre y hasta $3 millones en pagos contingentes vinculados a hitos.
El cierre está previsto para el cuarto trimestre de 2025, sujeto al cumplimiento o renuncia de las condiciones habituales de cierre. Merit hizo referencia a medidas no GAAP en su comunicado de prensa y afirmó que una conciliación cuantitativa a GAAP no está disponible sin un esfuerzo irrazonable.
Merit Medical Systems (MMSI)는 Pentax of America, Inc., PENTAX Medical의 자회사로부터 C2 CryoBalloon 기기 및 관련 기술을 인수하기 위한 확정 자산 매매 계약을 발표했습니다. 총 매매대금은 $22 million이며, 그 중 종가 시점에 현금으로 $19 million이고 최대 $3 million의 조건부 지급이 이정표와 연계되어 있습니다.
종료는 2025년 4분기에 예정되어 있으며, 일반 종결 조건의 충족 또는 면제 여부에 따라 달라집니다. Merit는 보도자료에서 비-GAAP 지표를 언급했고 GAAP에 대한 정량적 조정은 과도한 노력 없이는 이용할 수 없다고 밝혔습니다.
Merit Medical Systems (MMSI) a annoncé un accord d'achat d'actifs définitif pour acquérir l'appareil C2 CryoBalloon et la technologie associée auprès de Pentax of America, Inc., une filiale de PENTAX Medical. Le prix d'achat total est de $22 millions, comprenant $19 millions en espèces à la clôture et jusqu'à 3 millions de dollars de paiements conditionnels liés à des jalons.
La clôture est prévue au cours du 4e trimestre 2025, sous réserve de l'accomplissement ou du renoncement des conditions de clôture usuelles. Merit a mentionné des mesures non-GAAP dans son communiqué de presse et a déclaré qu'un rapprochement quantitatif vers les GAAP n'était pas disponible sans effort déraisonnable.
Merit Medical Systems (MMSI) hat eine endgültige Asset-Kaufvereinbarung bekannt gegeben, um das C2 CryoBalloon-Gerät und die zugehörige Technologie von Pentax of America, Inc., einer Tochtergesellschaft von PENTAX Medical, zu erwerben. Der gesamte Kaufpreis beträgt $22 Millionen, einschließlich $19 Millionen Bargeld zum Closing und bis zu $3 Millionen an bedingten Zahlungen, die an Meilensteine gebunden sind.
Der Abschluss wird voraussichtlich im vierten Quartal 2025 erfolgen, vorbehaltlich der Erfüllung oder dem Verzicht auf die üblichen Abschlussbedingungen. Merit verwies in seiner Pressemitteilung auf non-GAAP-Maßnahmen und gab an, dass eine quantitative Offenlegung gegenüber GAAP ohne unverhältnismäßigen Aufwand nicht verfügbar ist.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported):
(Exact name of registrant as specified in its charter)
|
| |||
(State or other jurisdiction of | (Commission | (I.R.S. Employer | ||
incorporation or organization) | File Number) | Identification No.) |
| ||
(Address of principal executive offices) | (Zip Code) |
(
(Registrant's telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
| Trading Symbol(s) |
| Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosure
On October 15, 2025, Merit Medical Systems, Inc. (“Merit”) issued a press release (the “Acquisition Press Release”) announcing it has signed a definitive asset purchase agreement with Pentax of America, Inc., a subsidiary of PENTAX® Medical, Inc., to acquire the C2 CryoBalloon™ device and related technology. The closing of the proposed transaction is expected to occur during the fourth quarter of 2025, subject to the satisfaction or waiver (in accordance with the provisions of the asset purchase agreement) of certain customary closing conditions.
Merit proposes to acquire the C2 CryoBalloon assets from Pentax of America, Inc. for total purchase consideration of $22 million, consisting of a $19 million cash payment at closing and potential contingent payments of up to $3 million payable upon meeting certain milestones.
A copy of the Acquisition Press Release is included as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Merit is making reference to non-GAAP information in the Acquisition Press Release. A quantitative reconciliation of such non-GAAP financial information to comparable GAAP financial information is not available without unreasonable effort.
The information contained in this Item 7.01 of this Current Report and in the attached Exhibit 99.1 is furnished pursuant to General Instruction B.2. of Form 8-K and shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing made by Merit under the Securities Act of 1933, as amended (the “Securities Act”), or the Securities Exchange Act of 1934, as amended (the “Exchange Act”).
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
The information included in this Current Report contains forward-looking statements about Merit that involve substantial risks and uncertainties. Merit intends such statements, and all subsequent forward-looking statements attributable to Merit, to be expressly qualified in their entirety by these cautionary statements and covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Exchange Act and Section 27A of the Securities Act. In some cases, forward-looking statements can be identified by the use of terminology such as “anticipate,” “believe,” “continue,” “estimate,” “expect,” “forecast,” “intend,” “may,” “might,” “plan,” “potential,” “project,” “will,” “would,” “seek,” “should,” “could,” “can,” “predict,” “potential,” “continue,” “objective” or other forms of these words or similar words or expressions, or the negative thereof or other comparable terminology. However, not all forward-looking statements contain such identifying words. All statements included in this Current Report, other than statements of historical fact, are forward-looking statements for purposes of the Exchange Act and the Securities Act, including any projections of earnings, revenues or other financial items, any statements of the plans and objectives for future operations, any statements concerning proposed new products or services, any statements regarding the integration, development or commercialization of the business or any assets acquired from other parties, any statements regarding future economic conditions or performance, and any statements of assumptions underlying any of the foregoing. Additionally, forward-looking statements include, among other things, inherent risks and uncertainties associated with Merit’s proposed acquisition of the C2 CryoBalloon device and related technology, Merit’s integration of the assets and operations proposed to be acquired from PENTAX Medical and its ability to achieve projected financial results, product development and other anticipated benefits of the proposed acquisition, and uncertainties as to whether Merit will achieve sales, gross and operating margin, net income and earnings per share performance consistent with its forecasts projected for the assets and operations proposed to be acquired from PENTAX Medical.
Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Merit’s actual results, levels of activity, performance or achievement to be materially different from those expressed or implied by these forward-looking statements, including those risks, uncertainties and other factors described in Merit’s Annual Report on Form 10-K for the year ended December 31, 2024 and Merit’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2025, and subsequent filings with the SEC.
2
All forward-looking statements included in this Current Report speak only as of the date made, are based on information available to Merit as of such date, and are subject to change. Merit assumes no obligation to update or revise any forward-looking statement. If Merit does update or correct one or more forward-looking statements, readers should not conclude that Merit will make additional updates or corrections. Merit’s actual results will likely differ, and may differ materially, from anticipated results. Readers should not unduly rely on any such forward-looking statements.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
EXHIBIT NUMBER |
| DESCRIPTION |
99.1 | Press Release, dated October 15, 2025, entitled “Merit Medical Signs Asset Purchase Agreement with PENTAX Medical to acquire C2 CryoBalloon Technology.” | |
104 | The cover page from this Current Report on Form 8-K, formatted in Inline XBRL |
3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
MERIT MEDICAL SYSTEMS, INC. | ||
Date: October 17, 2025 | By: | /s/ Brian G. Lloyd |
Brian G. Lloyd | ||
Chief Legal Officer and Corporate Secretary | ||
4
FAQ
What did Merit Medical (MMSI) announce?
What is the total purchase price for the C2 CryoBalloon technology?
When is the acquisition expected to close?
Who is the seller in this transaction?
Does Merit provide GAAP reconciliations for referenced non-GAAP metrics?
Are there conditions to closing?
